New York, New York--(Newsfile Corp. - March 8, 2022) - Plantable® Health Inc. (NEO: PLBL) ("Plantable" or the "Company") today provides an update in light of International Women's Day on its Breast Cancer Trial at the Memorial Sloan Kettering Cancer Center ("MSK"), which aims to study the efficacy of Plantable as a whole food plant-based dietary intervention to help reduce the independent risk factors associated with breast cancer and other metabolic markers associated with chronic disease. In the U.S. alone, about 1 in 8 women are diagnosed with invasive breast cancer over the course of their lifetime. As the first woman CEO of a NEO Exchange listed company, Dr. Nadja Pinnavaia is seeking solutions to combat these challenges that affect women worldwide as part of Plantable's mission to reduce breast cancer and empower women to protect and improve their own health.
The Breast Cancer Trial which is led by Neil Iyengar, MD, a breast medical oncologist and clinical investigator at MSK, is a study of the body's response to exercise and adherence to a whole food, plant-based diet, through a plant-based diet in overweight postmenopausal women with breast cancer. The objective of this trial is to prove that exercise combined with a whole food, plant-based diet may help slow the growth of cancer by decreasing aromatase levels and promote other positive changes in the body such as weight loss. High levels of aromatase are common in overweight women and can fuel some forms of breast cancers. This active trial is working with breast cancer patients through a Phase 2 randomized control trial and has currently enrolled 45% of participants.
"I am thrilled to collaborate on this scientifically rigorous trial," said Dr. Neil Iyengar. "This trial looks at a precision plant-based nutrition intervention plus structured exercise in the same way that researchers would develop a new drug for cancer treatment. The evidence generated by this study so far indicates that there could be the potential to transform breast cancer treatment by including prescribed dietary and exercise modification in order to improve response to standard cancer treatments."
The Breast Cancer Trial is currently accruing patients and enrollment is anticipated to be completed early next year with reporting of results anticipated shortly thereafter. The study is one of the first randomized controlled trials of a precision nutrition and exercise intervention in the oncology setting, and results are anticipated to shift the paradigm in medical oncology practice. The evidence base established by this trial will be used to support interventions in other cancers and to incorporate precision nutrition interventions into standard oncology care.
CEO Dr. Nadja Pinnavaia stated: "Today is a day to celebrate all women worldwide and empower women to optimize their health and well-being. I started Plantable after yet another diagnosis of cancer in the family. I lost my mother to breast cancer and as such, I am so proud to bring forward clinically proven solutions to reduce recurrent breast cancer risk."
About Plantable® Health Inc.
Plantable is a clinically supported, lifestyle intervention program that combines behavioral psychology, neuroscience, and nutritional science to transform health and wellness. Plantable drives healthy weight loss and an improvement in performance, health, and well-being by bringing together whole food, plant-based meals, personalized coaching support and lifestyle educational tools to empower people to change their dietary habits. To view the Company's products and become a customer, please visit plantable.com or click the link here: https://plantable.com
If you are interested in investing in the Company and would like more information, click the link here: http://invest-plantable.com
Become a part of the Plantable investor community on WhatsApp by joining the link here: https://chat.whatsapp.com/CNupoG2sVitJRhzpfGJGHt
On behalf of the Board of Directors,
Dr. Nadja Pinnavaia
Chief Executive Officer
For investor inquiries please contact:
Corporate Communications and Investor Relations
Cautionary Note Regarding Forward-Looking Information
Certain statements contained in this news release constitute forward-looking statements as defined under applicable securities laws. All statements in this news release, other than statements of historical facts, that address events or developments that management of the Company expect, are forward-looking statements. Specifically, the references in this news release to the benefits the Company expects to gain from the anticipated successful completion of the Breast Cancer Trials, and the expected market opportunity arising from Plantable's alternative healthcare programs becoming a recommended alternative to traditional medication both constitute forward-looking statements. Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company's control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements, see "Notice to Investors - Forward-Looking Information" and "Risk Factors" in the Prospectus. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, save and except as may be required by applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/115934